ABBV-466
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 24, 2026
ABBV-466, A NOVEL DUAL-TARGETING THERAPY, LEADS TO ENDOSCOPIC REMISSION IN MODERATE-TO-SEVERE CROHN'S DISEASE: PRIMARY RESULTS AND MOLECULAR PROFILING FROM THE PHASE 2A TARGET-CD STUDY
(UEGW 2026)
- No abstract available
Clinical • Late-breaking abstract • P2a data • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1